ARADyAL (Asthma, Adverse Drug Reactions and Allergy Network) is a thematic network of translational cooperative health research (RETICS), which combines innovative approaches in the areas of immunology, genetics, nanomedicine, pharmacology, and chemistry, with a special interest in the research of new biomarkers and the design and evaluation of new intervention strategies in allergic patients with severe phenotypes.

The RETICS are organizational structures formed by the association to the Carlos III Health Institute of a variable group of centers and research groups in biomedicine, of multidisciplinary character, which depend on the different public administrations or the private sector and belonging to at least four Autonomous Communities, which have the objective of carrying out cooperative research projects of general interest.

They respond to the priorities of the State Plan for Scientific and Technical Research and Innovation (“Plan Estatal de Investigación Científica y Técnica y de Innovación”) 2013-2016 in the health field and integrate the different types of research as a strategy to shorten the interval between the production of new knowledge and its transfer and real applicability in medical practice.

The general objective of the RETICS is to promote collaboration between research groups in the National Health System working on related topics while facilitating the structuring of the research carried out there. RETICS have the financial support of the European Regional Development Fund (ERDF). A way of doing Europe.